Ранняя стадия поражения почек у больных гипертонической болезнью: клиническое значение, принципы профилактики
Диссертация
Согласно современным представлениям центральным звеном развития гипертонической нефропатии (ГНП) является неиммунное поражение почечных сосудов. Высокая гипертензия через гемодинамические факторы (напряжение сдвига и круговой стресс) активирует/повреждает почечные эндотелиоциты, вызывая их дисфункцию. Дисфункция эндотелия внутрипочечных сосудов в сочетании с метаболическими нарушениями… Читать ещё >
Содержание
- Глава I. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Эпидемиология гипертонической болезни (ГБ)
- 1. 2. Поражение почек при ГБ
- 1. 3. Морфогенез поражения почек при ГБ — гипертоническая нефропатия (ГНП)
- 1. 4. Патогенез ГНП
- 1. 4. 1. Роль эндотелиальной дисфункции в патогенезе ГНП
- 1. 4. 2. Ангиогенные факторы роста при ГБ
- 1. 5. Современные критерии поражения почек при ГБ
- I. 5.1. Роль микроальбуминурии (МАУ) в оценке ГНП
- 1. 5. 1. 1. МАУ и сердечно-сосудистые факторы риска (ФР)
- 1. 5. 2. Значение скорости клубочковой фильтрации как критерия ГНП
- 1. 6. Связь поражения почек и органов сердечно-сосудистой системы при ГБ — рено-кардио-васкулярные взаимоотношения
- 1. 6. 1. Ультразвуковая диагностики поражения почек и других органов-мишеней — сердца и общих сонных артерий при ГБ
Список литературы
- Анисимова Л.П. Ультразвуковые методы исследования структуры и кровоснабжения почек при различных формах артериальной гипертензии. Диссерт.. канд. мед. наук.- М., 1995.
- Арутюнов Г. П., Чернявская Т. К. и др. Микроальбуминурия: клинические аспекты и пути медикаментозной коррекции // Клин. Фармакол. Тер.-1999.-№ 3.-С. 23−28.
- Бобкова И.Н. Клеточно-молекулярные механизмы нефротоксического действия протеинурии: роль в прогрессировании хронического гломерулонефрита, пути воздействия: Автореф. дис.. .д-ра. мед. наук. -М., 2007.- 47с.
- Бобкова И.Н., Чеботарева Н. В., Рамеев В. В. и др. Роль эндотелиальной дисфункции в прогрессировании хронического гломерулонефрита, современные возможности ее коррекции // Тер.арх.-2005.-№ 6.-С.92−96.
- Галицин П.В., Литвин А. Ю., Чазова И. Е. Синдром обструктивного апноэ во время сна и дисфункция эндотелия // Кардиологический вестник.- 2007.-Т.2.-Ж2.-С.71−76.
- Добронравов В.А., Смирнов A.B., Трофименко И. И. Роль гипергомоцистеинемии в развитии кардиоренального континуума // Качество жизни. Медицина -2006.-№ 4.-С.55−59.
- Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр).-М., 2008.-32с.
- П.Кунцевич Г. И., Барабашкина A.B., Аносов O.A. Возможности дуплексного сканирования с цветовым допплеровским картированием в диагностике микроангиопатий у больных сахарным диабетом // Визуализация в клинике.-1995.-№ 7.-С. 17−20.
- Кутырина И.М., Руденко Е. У., Дзитоева М. Ю. Ремоделирование сосудов при хронической почечной недостаточности // Клин.мед.-2005.-№ 2.-С. 16−22.
- Кутырина И.М., Руденко Т. Е., Швецов М. Ю. Кушнир В.В., Факторы риска сердечно-сосудистых осложнений у больных на додиализной стадии хронической почечной недостаточности // Тер.арх.-2006.-№ 5-С.45−50.
- ЛангГ.Ф. Гипертоническая болезнь. М.: Медицина, 1950.- 496с.
- Ли O.A., Бобкова H.H., Козловская Л. В. Концентрация в моче матриксных металлопротеиназ и их ингибиторов как показатель, характеризующий течение хронического гломерулонефрита // Клиническая нефрология.-2009.-№ 1.-С.50−54.
- Моисеев B.C. Метаболические аспекты гипертонической болезни // Тер.арх.-1997.- № 9.-С. 16−18.
- Мухин H.A., Фомин В. В., Моисеев C.B. Микроальбуминурия-интегральный маркер кардио-ренальных взаимоотношений при артериальной гипертонии // Журнал сердечная недостстончоть.-20 078.-С. 301−305.
- Мухин H.A., Козловская Л. В., Бобкова И. Н. и др. Индуцируемые протеинурией механизмы ремоделирования тубулоинтерстиция и возможности нефропротекции при гломерулонефрите // Вестник РАМН.-2005.-№ 1.-С.З-8.
- Мухин H.A., Кутырина И. М., Козловская Л. В. Протеинурическое ремоделирование тубулоинтерстиция мишень нефропротективной стратегии при хронических заболеваниях почек // Тер.арх.-2002.-№ 6,-С.5−11.
- Мясников А.Л. Гипертоническая болезнь.-М.: Медицина, 1954.-392с.
- Паунова С.С. Ангиотензин II современное представление о патогенезе нефросклероза // Нефрология и диализ.-2003.-Т.5.-№ 4.-С.353−356.
- Постнов Ю.В. Первичная гипертензия клеточный рессетинг и переключение почки // Кардиология.- 1993.-№ 8.-С. 7−15.
- Пыков М.И. Ультразвуковое исследование почечного кровотока у детей // Визуализация в клинике.-1996.-№ 9.-С. 18−22.
- Серов В.В., Пальцев М. А. Почки и артериальная гипертензия М.:Медицина, 1993.-256 с.
- Смольянинова Н.Г. Оценка почечного кровотока ультразвуковыми методами с применением компьютерного анализа при различных формах артериальной гипертонии: Диссерт. .канд. мед. Наук,-Москва, 1998.
- Тареева И.Е., Кутырина И. М. Неверов И.Е. Пути торможения неиммунного прогрессирования нефритов // Клиническая медицина.- 1995.-№ 3.-С.80−83.
- Тареева И.Е., Кутырина И. М., Николаев А. Ю. Пути торможения развития хронической почечной недостаточности // Тер.арх. -2000.-№ 6.-С.9−14.
- Фомин В. В, Моисеев С. В, Швецов М. Ю. Артериальная гипертония при ишемической болезни почек: клинические особенности и течение // Тер.арх.-2005.-№ 6.-С.27−32.
- Хирманов В.Н. Факторы риска: микроальбуминурия // Тер. Архив -2004.- № 9.-С.78−84.
- Чеботарева Н.В., Бобкова И. Н., Козловская JI.B. Молекулярные механизмы интерстициального фиброза при прогрессирующих заболеваниях почек // Нефрология и диализ.-2006.-Т.8.-№ 1.-С.26−35.
- Afrati M. D, Vitseva О., Tanriverdi К. et al. Compensatory mechanisms influence haemostasis in setting of eNOS deficiency // Am. J. Physiol. Heart. Circ. Physiol.-2005.-V.288 (Suppl.4).-P. 1627−1632.
- Amann K., Wanner C., Ritz E. Cross-Talk between the Kidney and the Cardiovascular System // J. Am. Soc. Nephrol.-2006.-V.17-P.2112−2119.
- Amaral S.L., Linderman J.R., Morse M.M. et al. Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF // Vicrocirculation.-2001.-V.8.-P.57−67.
- Amit X., Garg В., Kiberd A., Clark W.F. et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III // Kidney International.-2002.-V.61 .-P.2165−2175.
- Andronico G., Ferrara L., Mangano M. et al. Insulin, sodium-lithium countertransport, and microalbuminuria in hypertensive patients // Hypertension.-1998.-V.3 l.-P.l 10−113.
- Antonios T.F., Rattrey F.M., Singer D.R.G et al. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension //Heart.-2003.-V.89.-P. 175−178.
- Bakris G.L. Clinical impotence of microalbuminuria in diabetes and hypertension // Curr. Hypertens. Rep.-2004.-V.6.-P352−356.
- Benndorf R., Boger R.H., Ergun S. et al. Angiotensin II type receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells // Circ. Res.-2001.-V.93.-P.438−447.
- Benndorf R.A., Appel D., Maas R., Schwedhelm E. et al. Telmisartan improves endothelial function in patients with essential hypertension // J. Cardiovasc. Pharmacol.-2007.- V.50.(Suppl.4)-P.367−371.
- Bergheim I., Guo L., Davis M.A. et al. Critical role of plasminogen activator inhibitior-1 in cholestatic liver injury and fibrosis // J. Pharmacol. Exp. Ther.- 2006.-V.316 (Suppl.2).-P.592−600.
- Betowski J., Kedra A. Asymmetric dimethylarginine (ADMA) as target for pharmacotherapy//Pharmacol. Rep.-2006.-V.58 (Suppl.2).-P.159−178.
- Bidani A. K. and Griffin K.A. Pathophysiology of hypertensive renal damage: implications for therapy//Hypertension. 2004.-V.44-P.595−601.
- Bidani A.K., Griffin K.A. Long-term renal consequences of hypertension for normal and diseased kidneys // Current Opinion in Nephrology Hyper.-2002.-V.il (Suppl.l).-P.73−80.
- Biggazi R., Bianchi S., Baldari D., Campese V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension//J.Hypertens.-1998.-V. 19 (Supl.9).-P.1325−1333.
- Boutaud A., Borza D.-B., Bondar O. et al. Type IV Collagen of the Glomerular Basement Membrane // J. Biol. Chem.-2000-V.275 (Suppl.39).-P.30 716−30 724.
- Bouton M.C., Richard B., Rossignol P. et al. The serpine protease-nexin 1 presents in rat aortic smooth muscle cells and is upregulated in L-NAME hypertensive rats // Arterioscler. Thromb. Vase. Biol.-2003.-V.23 (Suppl.l).-P.142−147.
- Brantsma A. H., Atthobari J., Bakker S J. L et al. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? // J. Am. Soc. Nephrol.- 2007.-V.18.-P.637−645.
- Brantsma A.H., Barker St., Hillege H.L.et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes // Diabetes Care -2005.-V.28.-P.2525−2530.
- Brosius F.C., Hostetter C.T.H., Kelepouris E., et al. Detection of Chronic
- Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease // Circulation.- 2006.-V.114.-P.1083−1087.
- Brown N.J., Muldowney J.A.S. Ill, Vaugham D.E. Endogeous NO regulates plasminogen activator inhibitor-1 during angoitensin-converting enzyme inhibition // Hypertension.-2006.-V.47(Suppl.3).-P.441−448.
- Brown, N.J., Nakamura Sh., Li J.M.A. et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomurolosclerosis in vivo // Kidney International.- 2000.-V.58 (Suppl.3).-P.1219−1227.
- Calvino J. Calvo C., Romero R. et al. Atherosclerosis profile and microalbuminuria in essential hypertension // Am. J. Kidney Dis.-1999.-V.34.- P.996−1001.
- Campese V.M., Park J. Use of antagonists of aldosterone in patients with chronic kidney disease: potential advantages and risks // Journal of Hypertension.-2006.-V.24.-P.2157−2159.
- Celermajer D.S., Sorensen K.E., Gooch V.M. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis // Lancet.-1922.-V.340.- P. 1111−1115.
- Chade A.R., Bentley M.D., Zhu X. et al. Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs // J. Am. Soc. Nephrol.- 2004.-V. 15.-P. 1816−1825.
- Chade A.R., Krier J.D., Textor S.C. et al. Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia// J. Am. Soc. Nephrol.-2006.-V.17.-P.3394−3403.
- Chang H., Shyu K.-G., Wang B.-W. et al. Regulation of hypoxia-inducible factor-1 a by cyclical mechanical stretch in rat vascular smooth muscle cells // Clin. Sci.-2003.-V. 105.-P.447−456.
- Chatziantoniou C., Dussaule J.C. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? // Am. J. Physiol. Renal Physiol.-2005.-V.289.(Suppl.2).-P.227−234.
- Chavakis E., Dimmeler S. Regolation of endoyhelial cell survival and apoptosis during angiogenesis // Arterioscler. Thromb. Vase. Biol.-2002.-V.22.-P.887−893.
- Chen J., Muntner P., Lee Hamm et al. The metabolic syndrome and chronic kidney disease in US adults // Ann. Intern. Med.-2004-V.140.-P.167−174.
- Christensen K.L., Mulvany M. J. Vasodilatation, not hypotension, improves resistance vessels design during treatment of essential hypertension: a literature survey // Journal of Hypertension-2001.-V.19 (Suppl.6).-P.1001−1006.
- Chuang-Tsai, Sisson T.H., Hattori N. et al. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1 //Am. J. Pathol.-2003 .-V. 163 (Suppl.2).-P.445−452.
- Cignarelli M., Lamacchia O. Obesity and kidney disease // Nutrition, Metabolism and Cardiovascular Diseases.-2007.-V.17.-P.757−762.
- Cirillo M., Senigalliesi K., Laurenzi M. Microalbuminuria in nondiabetic adults. Relation of blood pressure, body mass index, plasma cholesterol levels and smoking: The Gubbio Population Study // Arch. Intern. Med.-1998.-V.158.-P. 1933−1939.
- Cirillo M., Stellato D., Laurezi M, et al. The Gubbio Stady Cjllaborative Research Group. Pulse pressure and isolated systolic Hypertatension: association with microalbuminuria // Kidney Int.-2 000.-V.58.- P.1211−1218.
- Cook N.R., Cutler J.A., Obarzanek E. et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trails of hypertension prevention // B.M.J.-2007.-V.334.-P.885−894.
- Cottone S., Mule G., Nardi E. et al. Microalbuminuria and early endothelial activation in essential hypertension // J. Hum. Hypertes.- 2007.-V.21 (Suppl.2).-P. 167−172.
- Cuspidi C., Meani S., Fusi V., Valerio C. et al. Isolated ambulatory hypertension and changes in target organ damage in treated hypertensive patients // J. Hum. Hypertens.-2005 -V.19 (Suppl.6).-P.471−477.
- Cuspidi C., Valerio C., Sala C., Esposito A. et al. Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure // Blood Press. Monit.-2008.-V.13 (Suppl.l).-P.7−13.
- Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling and functions during vascular morphogenesis and neovessels stabilization// Circ Res.-2005.-V.97.-P. 1093−1107.
- Dayal S., Lentz S.R. ADMA and hyperhomocysteinemia // Vase. Med.-2005.-V.10.-P.27−33.
- De Jong P.E., Verhave J.C., Pinto-Sietsma S .J., Hillege H.L. Obesity and target organ damage: the kidney. // Int.J.Obes.Relat.Metab.Disord.-2002.-V.26 (Supp.l4)-P.21−24.
- De Zeeuw D., Parving H.-H., Henning R.H. Micrialbuminuria as an early marker for cardiovascular disease // J. Am. Soc. Nephrol. -2006.-V.17.-P.2100−2105.
- Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. Segural J., Campo G., Gril P. et al // J.Am. Soc. Nephrol.- 2004.-V.15.-P.1616−1622.
- Dimmeler S., Fisslthaler B., Fleming I. et al. Activation of nitric oxide synthase in endothelial cells by Alct-dependent phosphorylation // Nuture.-1999.-V.399.-P.601−605.
- Domronglcitchaiporn S., Piyamitr S., Kitiyakara C. et al. Risk factors fordevelopment of decreased kidney function in a southeast asian population: a 12-year cohort study // J. Am. Soc. Nephrol.-2005.-V.16.-P.791−799.
- Droge. W. Oxidative aging and insulin receptor signaling // J. Gerontol. Biol. Sei. Med. Sei. -2005.-V.60 (Suppl.l 1).-P. 1378−1385.
- Dyer A.R., Greenland P., Elliot P. et al. Evaluation of measures of urinary albumin excretion in epidemiologic studies // Am. J. Epidemiol.-2004.-V. 160.-P. 1122−1131.
- Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis //Hypertension.-2001.-V.37.-P. 1047−1052.
- Eddy A.A. Plasmingen activator inhibitor-1 and the kidney // Am. J. Physiol. Renal. Physiol.-2002.-V.283.-P.209−220.
- Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-lin chronic kidney disease: evidence and mechanisms of action // J. Am.Soc.Nephrol.-2006.-V.17.-P.2999−3012.
- Emaueli C., Salis M.B., Stacca T. et al. Angiotensin ATI receptor signaling modulates reparative angiogenesis induced by limb ischemia // Br .J. Pharmacol.- 2002.-V.135.-P.87−92.
- Endemann D.H., Schiffrin E.L. Endothelial dysfunction // J. Am. Soc. Nephrol.-2004-V. 15 .-P. 1983−1992.
- Fang Y., Mu J.J., He L.C. et al. Salt loading on plasma asymmetrical dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive Asians // Hypertension.-2006.-V.48 (Suppl.4).-P.724−729.
- Fay W.P., Garg N., Sunkar M. Vascular functions of the plasminogen activation system // Arterioscler. Thromb. Vase. Biol.- 2007.-V.27.-P. 12 311 237.
- Feig D.I., Johnson R.J. Hyperuricemia in childhood primary hypertension // Hypertension.-2003.-V.42.-P.247−252.
- Feig D.I., Nakagawa T., Karumanchi S.A., Oliver W.J. et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension //
- Kidney Int.-2004.-V.66.-P.281−287.
- Felmeden D.C., Spencer C.G., Belgore F.M. et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factor management // Am. J. Hypertens.-2003.-V.16.-P.l 1−20.
- Fernandez-Llama P., Jordi B. Is albuminuris a marker of arterial remodeling? //J. Arter. Thromb.Vasc.-2008.-V.26.-P.633−635.
- Fogo A.B. Glomerular hypertension, abnormal glomerular growth and progression of renal diseases // Kidney International.-2000.-V.57 (Supple.75).-P. 15−21.
- Fogo A.B. Mechanisms of progression of chronic kidney disease // Pediatr. Nephrol.- 2007.-V.22.-P.2011−2022.
- Folkow B. Structure and function of the arteries in hypertension // Am. Heart J.- 1987.-V.l 14.-P.938−948.
- Fox I.H., Kelley W.N. Studies on the mechanism of fructose-induced hyperuricemia in man //Metabolism.- 1972.-V.21.-P.713−721.
- Frauchiger B., Nussbaumer P., Hugentobler M. et al. Duplex sonographic registration of age and diabetes-related loss of renal vasodilatoryresponse to nitroglycerine //Nephrol. Dial. Transplant.-2000.-V.15.-P.827−832.
- Frid M.G., Kale V.A., Stenmark K.R. Mature vascular endothelium can give rise to smooth muscle cell via endothelial-mesenchymal trabsdifferentiation // Cellular. Biol.-2002.-V.90.-P.l 189−1196.
- Galesic K., Brkljacic B., Sabljar-Matovinovic M. et al. Renal vascular resistance in essential hypertension: duplex-Doppler ultrasonographic evaluation //Angiology. 2000.- V.51 (Suppl.8).-P.667−75.
- Ganau A. Agein induces left ventricular concentric remodeling in normotensive subjects // J.Hypertens.-1995.-V.13-P.1818−1822.
- Gansevoort R.T., Bakker St.J.L., de Jong Paul E. Early detection of progressive chronic kidney disease: is it feasible? // J. Am. Soc. Nephrol.-2006.-V.17.-P.1218−1220.
- Garg A.H., Kiberd B.A., Clark W.F. et al Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III // Kidney Int.-2002.-V.61.-P.2165−2175.
- Garg J.P., Bakris G.L. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease // Vasc.Med.-2002.-V.7.-P.35−43.
- Gasser P., Buhler F.R. Nailfold microcirculation- in normotensive and essential hypertensive subjects, as assessed by video-microscopt // J. Hypertens.-1992.-V.10.-P.83−86.
- Gerstein H.C., Mann J.F.E., Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals // JAMA.-2001 .-V.286.-P.421 -426.
- Gokce N., Keaney J., Vita J. Endotheliopathies: clinical manifestations of endothelial dysfunction. In: Throbosis and Hemorrage, ed. by Loscalzo J. and Shafer A. Baltimore, MD: Williams and Willdns, 1998, 901−924.
- Goldblatt H. The renal origin of hypertension // Physiol. Rev.- 1947.-V.27.-P. 120−165.
- Goldstein D.S. Plasma catecholamines and essential hypertension // Hypertension.-1983 .-V.5 .-P.86−99.
- Goligorsky M.S. Endothelial cell dysfunction: can’t live with it, how to live without it // A.J.P.Renal Physiol.-2005.V.288.-P.871−880.
- Goro O., Ramtin A., Frutkin A. D. et al. Transforming growth factorbeta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways // Arterioscler. Thromb. Vase. Biol.-2006.-V.26.-P.737−743.
- Goumenos D.S., Tsakas S., Meguid A., Nahas El. et al. Transforming growth factor-bl in the kidney and urine of patients with glomerular disease and proteinuria//Nephrol. Dial. Transplant.-2002.-V.17.-P.2145−2152.
- Gouverneur M., Van Den Berg B., Nieuwdorp M. et al. Vasculoprotective properties of the endothelial glycocalyx: effects of fluid shear stress // Journal of Internal Medicine.-2006.-V.259.-P.393−400.
- Grassi G. Involvement of neuroadrenergic factorsin hypertensive vascular remodeling: myth or reality? // J.Hypertens.-2003.-V.21.-P.2239−2241.
- Gratze P., Dechend R., Stocker C. et al. Novel role for inhibitor of Differentiation 2 in the genesis of angiotensin II-induced hypertension // Circulation.-2008.-V. 117.-P.2645−2656.
- Griffin K.A., Kramer H., Bidani A.K. Adverse renal consequences of obesity // Am. J. Physiol. Renal Physiol.-2008.-V.294 (Suppl.4).-P.685−696.
- Griffin K.A., Bidani A.K. Progression of renal disease: renoprotective specifity of rennin-angiotensin system blockade // J.Am.Soc.Nephrol.-2006.-V.l-P.1054−1065.
- Gueler F., Rong S., Mengel M. et al. Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection // J. Immunology.- 2008.- V. 181 .-P. 1179−1189.
- Gupta K., Iskandar S.S., Daeihagh P., Ratliff H.L., Bleyer AJ. Distribution of pathologic findings in individuals with nephritic proteinuriaaccording to serum albumin // Nephrol Dial Transplant.- 2008.-Y.23 (Suppl. 5). P.1595−1599.
- Guyton A.C., Hall J.E., Lonmeier T.E. The many roles of the kidney in arterial pressure control and hypertension // Can.J.Physiol.Phann.-1981.-V.59.-P.-513−519.
- Halbesma N., Kuiken D.-S., Brantsma A.H. et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening // J. Am. Soc. Nephrol.-2006.-V. 17.-P.2582−2590.
- Haroun M.K., Jaar B.G., Hofman S.C. et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington county, Maryland // J.Am.Soc.Nephrol.-2003.-V.14 (Suppl. 11).-P.2934−2941.
- Heine G.H., Reichart B., Ulrich Ch. et 11. Do ultrasound renal resistance indices reflect systemic rather than renal vascular damage in chronic kidney disease? // Nephrol. Dial. Transplant.- 2007.-V.22.- P. 163 170.
- Hillege. H.L., Fidler V., Dierclcs G.F.H., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population // Circulation.-.2002.-V.106-P. 1777−1779.
- Hou Y.Z., Okada K., Okamoto Ch. et al. Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II-Mediated Vascular Remodelling // Ather. Thromb.Vas. iol.-2008.-V.28.-P. 1257−1261.
- Hricak H., Lieto R.P., Crus C. Renal parenchymal disease: sonographic histologic correlation // Radiology.-1982.V. 144.- p. 141−144.
- Ieiper J., Vallance P. Biological significance of endogenous methylarginins that inhibit nitric oxide synthases // Cardiovascular Research.- 1999.-V.43 (Suppl.3).-P.542−548.
- Iida S., Baumbach G.L., Lavoie J.L. et al. Spontaneous stroke in a genetic model of hypertension in mice // Stroke.- 2005.-V.36 (Suppl.6).1. P.1253−1258.
- Inoue M., Oishi C., Shimajiri Y. et al. Clinical usefulness of measurement of urine type IV collagen for detection of early phase of nephropathy in type 2 diabetic patients // Rhinsh. Byori.-2008.-V.56 (Suppl.7).-P.564−569.
- Intengan H.D., Schiffrin E.L. Structure and Mechanical properties of Resistance Arteries in Hypertension: Role of Adhesion Molecules and Extracellular Matrix Determinants // Hypertension.-2000.-V.36.-P.312−318.
- Ishimura E., Nashisava Y. Intrarenal hemodynamic abnormalities in diabetic nephropathy measured by duplex Doppler sonography // Kidney Int.-1997.-V.51(suppl.6).-1920−1927.
- Iversen B.M., Sekse' I., Ofstad J. Resseting of renal blood flow autoregulation in spontaneously hypertensive rats // Am. J. Physiol.-1987.-V.252.-P.480−486.
- Johnson G. The anatomy of Bright’s disease: the arteriocapillary fibrosis of William Gull and Dr. Sutton//B.M.G.- 1972.-V.1-P.604−605.
- Johnson R.J., Feig D.I., Nakagava T. Pathogenesis of essential hypertension: historical paradigms and modern insights // J. Hypertens.-2008.-V.26.-P.381−391.
- Jones C.A., Francis M.E., Eberhardt M.S. et al. Microalbuminuria in the US population: third National Helth and Nutrition Examination Survey // Am.J. Kidney Dis.-2002.-V.39.-P.445−459.
- Jong P.E., Gansevoort R.T., Bakker S.J.L. Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength? // J. Nephrol.-2007.-V.20.-P.375−380.
- Jose P.A., Eisner G.M., Felder R.A. Dopamine and the kidney: a role in hypertension? // Curr. Opin. Nephrol. Hypertense.-2003.-V.12.P.189−194.
- Jurewicz M., McDermott D.H., Sechler J.M. et al. Human T and natural killer cells posses a functional renin-angiotensinsystem: further mechanisms of angiotensin II-induced inflammation // J.Am. Soc. Nephrol.2007.-V.18.-P.1093−1102.
- Kaikita K., Fogo A.B., Ma L., et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition // Circulation.-2001.-V.104.-P.839−844.
- Kalantar-Zadeh K. So, is leptin good or bad in chronic kidney disease? // Obesity.-2007.-V.15.-P.1343−1344.
- Kang D.H., Kanellis J., Hugo C. Et al. Role of the micrivascular endothelium in progressive renal disease // J. Am. Soc. Nephrol.-2002.-V.13.-P.806−816.
- Kett M., Bergstrom G., Alcorn D. et al. Renal vascular resistance properties and glomerular protection in early established SHR hypertension //Journal of Hypertension.- 2001.-V.19 (Suppl.8).-P.1505−1512.
- Khan R., Agrotis A., Bobik A. Understanding the role of transforming growth factor-?l in intimal thickening after vascular injury // Cardiovascular research.-2007.-V.74.-P.223−234.
- Kielstein J.T., Bode-Boger S.M., Frolich J.C. et al. Asymmetric dimethylarginine, blood pressure and renal perfusion in elderly subjects // Circulation.-2003 .-V. 107.-1891 -1894.
- Kielstein J.T., Boger R.H., Bode-Boger S.M., Frolich J.C. et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease // J. Am. Soc. Nephrol.-2002.-V.3.-P. 170−176.
- Kielstein J.T., Donnerstag F., Gasper S. et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans // Stroke.-2006.-V.37(Suppl. 8).-P.2024−2029.
- Klag M.J., Whelton P.K., Randall B. Et al. Blood pressure and endstage renal disesase in men //N. England. J. Med.-1996.-V.334.-P.13−18.
- Klahr S., Mirrisey J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease // Kidney International.-2000.- V.57 (Suppl.75).-P.7−14.
- Kooman J.P., van der Sande F.M., Leunissen K.M.L. Sodium, blood pressure and cardivascular pathology: is it all volaemia? // Nephrol Dial Transplant.-2004.-V. 19.-P. 1046−1049.
- Krinenberg F, Ritz E., Konig P., Kraatz G., Lhotta K. Apolipoprotein-A serum concentrations are elevated in patient with mild and moderate renal failure // J. Am. Soc. Nephrok-2002.-V.13.-P.461−469.
- Kumper P., Gueler F., Rong S. et al. Leptin is a coactivator of TGF-? in unilateral ureteral obstructive kidney disease // Am. J. of Renal Physiol.-2007.-V.93 .-P. 1355−1362.
- Kuwahara .F, Kai H., Tokuda K. et al. Hypoxia-inducible factor-la-vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta // Hypertension.-2002.-V.39.-P.46−50.
- Langenfeld M.R., Forst T., Hohberg C. et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus // Circulation.-2005.-V.l 11.-P.2525−2531.
- Leiper J., Vallance P. Biological significance of endogenous methylarginins that inhibit nitric oxide synthases // Cardiovascular Research.-199.-V.43 (suppl.3).-P.542−548.
- Lekatas I., Koulouris S., Triantafyllou K., et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction// Int. J. Cardiol.-2006.-V.106(Suppl.2).-P.218−223.
- Leoncini G., Martinoli C., Viazzi F., Ravera M. et al. Changes in renal resistive index and urinary albumin excretion in hypertensive patients underlong-term treatment with lisinopril or nifedipine GITS // Nephron.-2002. V.90 (Suppl.2).-P.169−173.
- Li B., Ogasavara A.K., Yang R. Et al. KDR (VEGF Receptor 2): Is the major mediator for hypothensive effect of VEGF // Hypertetns.-2002.-V.39.-P.1095−1100.
- Lip G.Y.H. Thrombogenesis, atherosclerosis and angiogenesis in vascular disease: a new triad // Angiology.-1996.- V.47(Suppl.2).-P.l 1 171 125.
- Llama F., Bover P. Is albuminuria a marker of arterial remodeling? // Jounal of Hypertension.- 2008.-Vol.26 (Suppl.4).-P.633−635.
- Long D.A., Mu W., Price K.L. et al. Vascular endothelial growth factor administration does not improve microvascular disease in solt-dependent phase of post-angiotensin II hypertension // Am. J. Physiol. Renal. Physiol.-2006.-V.291 .-P. 1248−1254.
- Long D.A., Price K.L., ITerera-Acosta J. et al. ITow does angiotensin II cause renal injury? // Hypertension.-2004.-V.43.-P.722−728.
- Loutzenhiser R., Bidani A, Chilton L. Renal miogenic response: kinetic attributes and physiological role // Circ. Res.-2002.-V.90.-P.1316−1324.
- Luis M. R. Renal function and cardiovascular risk in hypertensive patients // J. of Hypertension.-2005.-V.23.-P.1787−1788.
- Lyon C.J., Law R.E., FIsueh W.A. Minireview: adiposity, inflammation and atherogenesis // Endocrinology.-2003.-V. 144 (Suppl.6).-P.2195−2200.
- Ma J., Weisberg A., Griffin J.P. et al. Plasminogen activator inhibitor1 deficiency protects against aldoterone-induced glomerular injury // Kidney International.-2006.-V.69.-P. 1064−1072.
- Ma Li-Jun, Nakamura S., Aidigier J.C. et al. Regression of glomerulosclerosis with high dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1 // J. Am. Soc. Nephrol.-2005.-V. 16.-P.966−976.
- Mahomed F.A. The etiology of Bright’s disease and the prealbuminuric state//Med. Chir. Trans.- 1874.-V.39-P.197−228.
- Makin A.J., Chung N.A., Silverman S.H., Lip G.Y.N. Vascular endothelial growth factor and tissue with established peripheral artery disease: a link between angiogenesis and thrombogenesis? // Am. J. Cardiol.-2003 .V. 104(Suppl.4).-P.397−404.
- Manunta P., Maillard M., Tantardini C. et al. Relationships among endogenous ouabain, alpha.-adducin polymorphisms and renal sodium handling in primary hypertension // Journal of Hypertension.-2008.-V.26(Suppl.5).-P.914−920.
- Martinez M. A- Alfonso M., Alvaro A.C. et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study//Journal of Hypertension.-2001.-V.19(Suppl.2).-P.319−326.
- Martinez-Lemus L.A., Hill M.A., Meininger G.A. The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure // Physiology 2009.-V.24.-P.45−57.
- Mazzali M., Kanellis J., Lin H. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism // Am. J. Physiol. Renal Physiol.-2002.-V.282.-P.991−997.
- McDonald S.P., Maguire G.P., Hoy W.E. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community // Nephrol. Dial. Transplant.-2003.-V.18 (Suppl.8).-P. 1555−1561.
- Mor F, Quintana FJ, Cohen I.R. Angiogenesis-inflammation cross-talk:vascular endothelial growth factor in secreted by activated T cells and induces Th 1 polarization//J. Immunol.-2004.-V.172.-P.4618−4623.
- Moritz A., Oldt M. Arteriolar sclerosis in hypertensive and nonhypertensive individuals // Am. J. Pathol.- 1937.-V.13.-P.679−728.
- Mule G., Nardi E., Cottone S., Cusimano P. et al. Impact of the metabolic syndrome on total arterial compliance in essential hypertension patients //J. Cardiometab. Syndr.-2007.-V.2 (Suppl.2).-P.84−90.
- Navar L. G, Kobori H., Prieto-Carrasquero M. Intrarenal angiotensin II and hypertension // Curr. Hypertens. Rep.-2003.-V.5.-P.135−143.
- Navar L.G. Renal autoregulation: perspectives from whole kidney and single nephron studies //Am. J. Physiol.-1978.-V.234.-P.357−370.
- NKF=K/DOQI. Clinical Practice guidlienes for chronic kidney disease: evaluation, classification, and stratification // Am. L. Kidney Dis.-2002.-V.39 (suppl.l).
- Noll G., Wenzel R.R., luscher T.F. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease // Mol. Cell. Biochem.- 1996.-V. 157.-P.259−267.
- Noon J.P., Walker B.R., Webb D.J. et al. Impaired microvascular dilatation and capillary rarefaction in young adults with predisposition to high blood pressure//J. Clin. Invest.-1997.-V.99.-P. 1872−1879.
- O’Riordan E., Mendelev N., Patschan S. et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation // Am. J. Physiol. Heart.
- Circ. Physiol.-2007.-V.292.-P.285−294.
- Ochodnicky P., Vettoretti S., Buikema H. et al. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to endorgan damage and therapeutic response // J. Nephrol.-2006.-V.19.(Suppl.3).-P.246−258.
- Oettgen P. Regulation of vascular inflammation and remodeling be ETS factors// Circ.Res.-2006.-V.99 (Suppl.l 1).-P.l 159−1166.
- Okubo K., Hayashi K., Wakino S. et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension // Hypertens. Res.-.2005.-V.28(Suppl.2).-P.181−189.
- Osanai T., Fujiwara N., Saitoh M. Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease // Blood Purif.-2002.-V.20.-P.466−468.
- Page E.L., Robitaille G.A., Poussegur J et al. Induction of hypoxia-inducible factor-1 a by transcriptional and translational mechanisms // J.Biol.Chem.-2002.-V.277.-P.403−409.
- Page I.H. The mosaic theory of arterial hypertension its interpretation//Perspect. Biol. Med.- 1967.-V.10.-P.325−333.
- Palaniappan L., Carneton M., Fortmann S.P. Association between microalbuminuria and the metabolic syndrome: NHANES III // Am.J.Hypertens.-2003.-V. 16.(Suppl. 11).-P.952−958.
- Park J.B., Charbonneau F., Shiffrin E.L. Con-elation of endothelial function in large and small arteries in human essential hypertension // Journal of Hypertension -2001.- V.19 (Suppl.3).-P.415−420.
- Park J.B.- Schiffrin E.L. Small artery remodeling is the prevalentearliers) form of target organ damage in mild essential hypertension // Journal of Hypertension 2001.-V.19(Suppl.5).-P.921−930.
- Patel T.V., Williams G.H., Fisher N.D. Angiotensinogen genotype predicts abnormal renal hemodynamics in young hypertensive patients // Jounal of Hypertension.-2008.V.26(Suppl.7).-P. 1353−1359.
- Perera G. Diagnosis and natural history of hypertensive vascular disease // Am. J. Med.-1948.-V.4-P.416−422.
- Perticone F., Sciaqua A., Maio R., Perticone M. et all. Asymmetric dimethyllarginine, L-arginine and endothelial dysfunction in essential hypertension//J. Am. Coll. Cardiol.-2005.-V.46(Suppl.3).-P.518−523.
- Perticone F., Maio R., Tripepi G., Tech S. et al. Endothelial dysfunction and mild renal insufficiency in essential hypertension // Circulation.-2004.-V.l 10.-P.821−825.
- Petersen L.J., Petersen J. R, Ladefoged S.D. The pulsatility index and the resistive index in patients with hypertension and chronic renal failure // Nephrol. Dial. Transplant.-1995.-V. 10 (Suppl.7).-P.20−26.
- Petersen L.J., Petersen J.R., Talleruphus U. et al. The pulsatility index and the resistive index in renal arteries. Associations with long-term progression in chronic renal failure //Nephrol. Dial.Transplant.-1997.-V. 12 (Suppl.7)-P. 1376−1379.
- Petitclerc E., Boutaud A., Prestayko A. et al. New Functions for Non-collagenous domains of Human Collagen Type IV // J. Biol. Chem.-2000.-V.275(Suppl.l 1).-P.8051−8061.
- Pickering G. The nature of essential hypertension // Lancet.- 1959-V.2.-P.1027−1028.
- Pontremoli R., Nicolella C., Viazzi F. et al. Microalbuminuria is an early marker of target organ damage in essential hypertension // Am. J. Hypertens.-1998.-V.l l (Suppl.4).-P.430−438.
- Poschl E., S chlotzer- S ehr ehardt U., Brachvogel B. et al. Collagen IV is essential for basement membrane stability but dispensable for initiation ofits assembly during early development // Development.- 2004.-V.131.-P.1619−1628.
- Prieto M., Rodriguez-Pena A., Arevalo M. et al. Effect of the long-term treatment with trandolapril on endoglin expression in rats with experimental renal fibrosis induced by renal mass reduction // Kidney Blood Press.Res.-2005.-V.28.-P.32−40.
- Pruijm M., Madaleune G., Riesen W. et al. Prevalence of microalbuminuria in the general population of Seychelles and strong association with diabetes and hypertension independent of renal markers // J. Hepertens.-2005.-V.28.-P.32−40.
- Radermacher J., Ellis S., Haller H. Renal resistance index and progression of renal disease // Hypertension.- 2002.-V.39.-P.699.
- Rastaldi M.P., Ferrario F., Giardino L. et al. Epithelial- mesenchymal transition of tubular epithelial cells in human renal biopsies // Kidney Int.-2002.-V.62.-P. 137−146.
- Ritz E. Cardiovascular risk factors and urinary albumin: vive la petite difference //J. Am. Soc. Nephrol.-2003.-V.14.-P.1415−1416.
- Ritz E. Metabolic syndrome: and emerging threat to renal function // Clin. J. Am. Soc. Nephrol.-2007.-V.2.-P.869−871.
- Ritz E., Benck U., Orth S.R. Acute effects of cigarette smoking on renal hemodynamics // Contrib. Nephrol. -2000.-V.130.-P.31−38.
- Rizzoni D., Porteri E., Guelfi D. et all. Endothelial dysfunction in small resistance arteries of patient with non-insulin-dependent diabetes mellitus // Jounal of Hypertension.- 2001 .-V. 19(Suppl.5).-P.913−919.
- Rodriguez-Iturbe B., Pons H, Quiroz Y. et al. Micophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure // Kydney Int.-2001 .-V.59-P.2222−2232.
- Rottman J.N., Bracy D.,. Malabanan C, Yue Z. et al. Contrasting effects of exercise and NOS inhibition on tissue-specific fatty acid and glucose uptake in mice // Am. J. Physiol. Endocrinol. Metab.-2002.-V.2831. Suppl. l).-.P.l 16−123.
- Ruilope L.M. Renal function and cardiovascular risk in hypertensive patients // J. Hypertension-2005.-V.23.-P. 1787−1788.
- Sane D.C., Anton L., Brosnihan K. B. Angiogenic growth factors and hypertension // Angiogenesis.- 2004.-V. 7.-P. 193−201.
- Santoro A, Bainotti A. Arterial hypertension and cardiovascular risk in patients with nephropathy // G. Ital. Nefrol.-2005.-V.22. (Suppl.31).-P.56−59.
- Sarzani R., Fabio S., Paolo D.-F. et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome and hypertension: an integrated view in humans // Journal of Hypertension.- 2008.-V.26 (Suppl.5).-P.831−843.
- Sautin Y.Y., Nakagawa T., Zharikov S., Johnson R.J. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress // Am. J. Physiol. Cell Physiol.-2007.-V.293.-P.584−596.
- Schaeffner E.S., Kurth T., Curban G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men // J.Am.Soc.Nephrol.-2003.-V.14 (Suppl.8).-P.2084−2091.
- Schiffrin E.L., Touyz R.M. Multiple actions of angiotensin II in hypertension: benefits of ATI receptor blockade // J. Am. Coll. Cardiol.-2003.-V.42 (Suppl.5).-P.911−913.
- Schrier R.W. Role of diminished renal function in cardiovascular mortality // J. Am. Coll. Cardiol.-2006.-V.47.- P. 1−8.
- Segura J., Campo C., Gil P. et al Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients // J. Am. Soc. Nephrol. 2004.-V. 15.-P. 1616−1622.
- Segura J., Campo C., Ruilope L.M. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension // Kidney Int.-2004.-V.66.-P.45−49.
- Shearer J., Fueger P.T., Vordnick B. et al. AMP kinase-induced skeletal muscle glucose but not long-chain fatty acid uptake is dependent on nitric oxide//Diabetes.-2004.-V.53 (Suppl.6).-P. 1429−1435.
- Shibuya M. Vascular endothelial growth factor receptor-1 (VEGF-1/Fit-l): a dual regulator for angiogenesis // Angiogenesis.- 2006.-V.9 (Suppl.4).-P. 225−230.
- Shimizu Y., Itoh T., Hougaku H., Nagai Y. et al. Clinical usefulness of duplex ultrasonography for the assessment of renal arteriosclerosis in essential hypertensive patients // Hypertens. Res.-2001.-V.24 (Suppl.l).-P.13−17.
- Shlipak M.G., Fried L.F., Crump C., Bleyer A.J. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency// Circulation.-2003 .-V. 107 (Suppl.l).- P.87−92.
- Sjogren L. S, Doroudi R., Gan L.-M.et all. Elevated intraluminal pressure inhibits vascular tissue plasminogen activatoe secretion and downregulates its gene expression // Hypertension.- 2000.-V.35.- P. 10 021 008.
- Smith H., Dixon J.D., Stringham J.R. et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis // Blood.-2006.-V.107 (Suppl.l).-P.132−134.
- Sorensen K.E., Celermajer D.S., Spiegelhalter D.J. et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility // Br. Heart J.-1995.-74 (Suppl.3).- P.247−253.
- Stengel B., Tarver-Carr M.E., Powe N.R. et al. Lifestyle factors, obesity and the risk of chronic kidney disease // Epidemiology.-2003.-V.14(Suppl.4).- P.479−487.
- Stoll M., Steckelings U.M., Paul M. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells // J. Clin. Invest.-1995.-V.95.- P.651−657.
- Stuveling. E.M., Baklcer S.J.L., Hillege H.L. et al. Biochemical riskmarkers: a novel area for better prediction of renal risk? // Nephrol. Dial. Transplant.-2005.-V.20.- P.497−508.
- Suzuki S., Ohtsuka S., Ishikawa K., Yamaguchi I. Effects of nicardipine on coronary, vertebral and renal arterial flows in patients with essential hypertension//Hypertens. Res.-2003.-V.26 (Suppl3).-P.193−199.
- Szczudlik A., Turaj W., Siowik A., et al. Microalbuminuria and Hyperthermia independently predict long-term mortality in acute ischemic stroke patients // Acta Neurol. Scand.-2003.-V.107.- P.96−101.
- Takeshita K., Hayashi M., lino S. et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction // Am. J. Pathol.- 2004.-V. 164 (Suppl.2).-P.449−456.
- Tayebjee M.H., MacFadyen R.J., Lip G.Y.H. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? // J Hypertens.-2003.-V.21.-P.2211−2218.
- Tian N., Gu J.W., Jordan S. et al. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension // Am. J. Physiol. Heart Circ. Physiol.- 2007.-V.292, — P. 10 181 025.
- Tsai W.C., Li Y.H., Huang Y.Y. et al. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension // Clin. Sci.- 2005.-V. 109 (Suppl.l).- P.39−43.
- Tublin M.E., Bude R.O., Piatt J.F. The resistive index in renal Doppler sonography: where do we stand? // A.J.R.-2003.-V.180.-P.885−892.
- Tuttle K.R. Renal manifestations of the metabolic syndrome // Nephrol. Dial. Transplant.-2005.-V.20.-P.861−864.
- Van der Harst P., Smilde T.D.J., Builcema H. et al. Vascular function and mild renal impairment in stable coronary artery disease // Arterioscler. Thromb. Vase. Biol.-2006.-V.26.-P.379−384.
- Van Guldener C., Stam F., Stehouwer C.D. Hyperhomocestaeinemiain chronic renal disease: Focus on transmethylation // Clin. Chem. Lab. Med.-2005.-V.43 .-P. 1026−1031.
- Vaughan D.E. PAI-1 and TGF-betai: unmasking the real driver of TGF-betai-induced vascular pathology // Arterioscler. Thromb. Vase. Biol.-2006.-V.26 (Suppl.4).-P.679−680.
- Vyzantiadis T., Karagiannis A., Douma S. et al. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension // Clin. Exp. Hypertens. 2006.-V.28 (Suppl.7).-P.603−609.
- Wang T.J., Gona P., Larson M. G, Levy D et al. Multiple Biomarkers and the risk of incident hypertension // Hypertension.- 2007.-V.49 (Suppl.3).-P.432−438.
- Watanabe S., Okura T., Kurata M., Irita J. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension// Clin. Exp. Hypertens.- 2006.-V.28(Suppl.5).-P.451−461.
- Wayanabe H., Sanada H., Shiqetomi S. et al. Urinary excretion of type IV collagen as specific indicator of progression of diabetic nephropathy // Nephron.-2000.-V.86 (Suppll. 1).-P.27−35.
- Weinberger M.H., Fineberg N.S. Sodium and volume sensitivity of blood pressure. Age and pressure change over time // Hypertension.- 1991.-V.18.-P.67−71.
- Xu J., Li.G., Wang P. et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure // J. Clin. Invest.-2005. -V.l 15 (Suppl.5).-P. 1275−1280.
- Yamamoto K., Tekeshita K., Kojima T., Takamatsu J. et al. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in thepathogenesis of thrombotic disorders in the elderly // Cardiovasc. Res.-2005.-V.66 (Suppl.2).-P.276−285.
- Yamanaka N., Shimizu A. Role of glomerular endothelial damage in prjgressive renal disease // Kidney Blood Press. Res.-1999.-V.22.-P. 13−20.
- Yayashi K., Epstein M., Loutzenhiser R. Pressure indused vasoconstriction of renal micro vessels in normotensive and hypertensive rats: studies in the isolated perfused hydronephrotic kidney // Circ. Res.-1989. V.65.-P.1475−1484.
- Zachary I., Gliki G. Signaling transduction mechanizmz mediating biolkgical actions of the vascular endothelial growth factor family // Cardiovas. Res.- 2001.V.49.-P.568−581.
- Zhang G., Kernan K.A., Collins S.J. et al. Plasmin (ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesnchymal transition: role of plasmin-activated signals // J. Am. Soc. Nephrol.-2007.-V.18.-P. 846−859.
- Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced buy not basic fibroblast growth factor-induced angiogenesis // L. Clin. Invest.- 1997.-V.99.-P.2635−2634.
- Zoccali C. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension // J. Am. Soc. Nephrol.-2006.-V.17 (Suppl. 2).-P.61−63.
- Zoccalli C., Maio R., Mallamaci F., Sesti G. et al. Uric acid and endothelial dysfunction in essential hypertension // J. Am. Nephrol.-2006,-V.17.-P.1466−1471.